HemoHim Manufacturer Kolmar BNH Receives NAI Classification from the US FDA


SEOUL, South Korea, ‘HemoHim,’ an immune-boosting health supplement from Kolmar BNH (KRX: 200130), has earned international recognition for its quality from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), enhancing its credibility in the global marketplace.

Kolmar BNH announced that its Sejong plant obtained a No Action Indicated (NAI) classification following an inspection by the U.S. FDA in September. This classification, which confirms that the facility fully complies with U.S. Current Good Manufacturing Practice (cGMP) standards for quality control, has further intensified Kolmar BNH’s competitiveness as a leading global Original Development Manufacturer (ODM) in the health supplement industry.

Source: BERNAMA News Agency

  • malaysiang

    Related Posts

    ASEAN Chairmanship: MAHB To Upgrade Key National Entry Points By Year-End

    SEPANG, Malaysia Airports Holdings Bhd (MAHB) has been asked to implement several upgrades at all national entry points in preparation for Malaysia’s ASEAN chairmanship next year, said Transport Minister Anthony Loke.

    He said this decision is in line…

    Bleak Deepavali For Siblings Who Lost Their Mother To COVID-19, YKM Extends Aid

    SEREMBAN, Deepavali celebrations have never been the same for M. Rajini, 17, Sumen Raj, 15, Kishor Raj, 14, and Bhuvana Raj, 10, since their mother’s death three years ago due to COVID-19.

    The siblings, who lost contact with their father for the past…